Skip to main content
The American Journal of Clinical Nutrition logoLink to The American Journal of Clinical Nutrition
editorial
. 2008 Dec 3;89(1):17–18. doi: 10.3945/ajcn.2008.27181

Can garlic reduce risk of cancer?123

Richard S Rivlin
PMCID: PMC2647709  PMID: 19056577

See corresponding article on page 257.

The use of garlic for medicinal purposes dates to antiquity. The Bible mentions garlic with regard to the Jews’ flight from Egypt. Garlic bulbs were found in tombs of the pharaohs, in Crete, and in ancient cultures throughout the world. Indeed, Hippocrates considered garlic to be a vital part of his therapeutic armamentarium (1).

Within recent years interest in garlic has grown greatly, particularly in relation to the prevention and treatment of cancer. Garlic has been found to contain a large number of potent bioactive compounds with anticancer properties, largely allylsulfide derivatives (2).

Garlic together with vitamins E and C reduced the incidence of precancerous gastric lesions in a large population in China (3). Garlic derivatives have been found to influence an increasing number of molecular mechanisms in carcinogenesis, including DNA adduct formation, scavenging of free radicals, mutagenesis, cell proliferation and differentiation, and angiogenesis (4). The growth rate of cancer cells is reduced by garlic, with cell cycle blockade that occurs particularly in the G2/M phase. Apoptosis is stimulated by garlic (5).

Diallylsulfide, a powerful garlic component, has been reported to inhibit oxidative stress caused by testosterone and to accelerate testosterone metabolism. We have postulated that in the early stages of prostate cancer, when sensitivity to testosterone is retained, the predominant effect of allium derivatives is to stimulate testosterone degradation and, in the later stages, to interfere with signal transduction (6).

Furthermore, garlic is a seleniferous plant, accumulating selenium from the soil against a concentration gradient. Selenium has many anticancer actions, particularly in control of genes involved in carcinogenesis.

The proliferation of human prostate cancer cell lines, both androgen sensitive (LNCaP) and androgen insensitive (PC-3), is inhibited by allium derivatives from garlic in a dose-dependent fashion (6). Stimulation of apoptosis has been related to inactivation of the Akt signaling axis. Rodent recipients of either androgen-sensitive or androgen-insensitive human prostate cancer cell lines show reduction in the serum concentration of prostate specific antigen.

In addition to inhibiting primary cancer, allium derivatives from garlic may further inhibit metastatic processes. In an androgen-independent prostate cancer mouse model, the water-soluble allium derivative, S-allyllmercaptocysteine, inhibited metastases to the lung and adrenal gland by 90% (7).

Despite these examples and the large base of basic research showing potent anticancer effects of various water- and fat-soluble derivatives of garlic (8), an evidence-based review in this issue of the Journal concludes that effects of garlic are only modest in reducing risk of cancer. Kim and Kwon (9) indicate that there is insufficient evidence to show any relation between garlic and cancer of the stomach, breast, lung, or endometrium. They further indicate that there is only very limited evidence of an effect of garlic on any of the gastrointestinal cancers (oral cavity, larnynx, esophagus, or colon) or the endocrine cancers (prostate and ovary) and cancer of the kidney.

How can one reconcile these divergent conclusions? To qualify as a health claim, the totality of publicly available scientific evidence (including evidence from well-designed studies) must show that such evidence truly supports the claim. In reality, the evidence-based analyses reported here and elsewhere rely largely on clinical trials with active agents and placebo controls.

The number of such trials that are considered scientifically sound in this analysis is remarkably few, and the number of subjects involved is generally small. Thus, the very strict criteria required to make a health claim may not be met by the limited number of studies conducted to date that are currently available. This article should serve as a stimulus to extend and broaden the interventional approaches to risk reduction by the use of garlic in susceptible populations, and eventually in the general public.

Acknowledgments

The author received research grants from Wakunaga of America Ltd.

REFERENCES

  • 1.Rivlin RS. Historical perspective on the use of garlic. J Nutr 2001;131:951S–4S [DOI] [PubMed] [Google Scholar]
  • 2.Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 2006;131:716S–25S [DOI] [PubMed] [Google Scholar]
  • 3.Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence and disease specific mortality. J Natl Cancer Inst 1993;85:1483–92 [DOI] [PubMed] [Google Scholar]
  • 4.Nagini S. Cancer chemoprevention by garlic and its organosulfor compounds – panacea or promise? Anticancer Agents Med Chem 2008;8:313–21 [DOI] [PubMed] [Google Scholar]
  • 5.Xiao D, Singh SV. Diallyl trisulfide, a consitutent of processed garlic, inactivates Akt to trigger mitochondrial translocation of BAD and caspase-medicated apoptosis in human prostate cancer cells. Carcinogenesis 2006;27:533–40 [DOI] [PubMed] [Google Scholar]
  • 6.Pinto JT, Rivlin RS. Garlic and other allium vegetables in cancer prevention. Heber D, Blackburn GL, Go VLW. Nutritional oncology San Diego, CA: Academic Press, 1999:393–403 [Google Scholar]
  • 7.Howard EW, Ling MT, Chua CW, et al. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. Clin Cancer Res 2007;13:1847–56 [DOI] [PubMed] [Google Scholar]
  • 8.Rivlin RS, Budoff M, Amagase H, et al. Significance of garlic and its constituents in cancer and cardiovascular disease. J Nutr 2006;136:713S–872S16484549 [Google Scholar]
  • 9.Kim JY, Kwon O. Garlic intake and cancer risk: an analysis using the Food and Drug Administration's evidence-based review system for the scientific evaluation of health claims. Am J Clin Nutr 2009;89:257–64 [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Clinical Nutrition are provided here courtesy of American Society for Nutrition

RESOURCES